Quercetin for Alzheimer's Disease

Also known as: Quercetin dihydrate

Quercetin's senolytic and anti-inflammatory properties target cellular senescence — an emerging driver of Alzheimer's neurodegeneration.

Mechanism of Action

As a senolytic (with dasatinib), quercetin selectively clears senescent neurons and glia that produce inflammatory SASP factors driving neurodegeneration. Independently, quercetin inhibits PI3K, activates sirtuins, suppresses NF-κB and NLRP3 inflammasome, and directly inhibits amyloid-beta aggregation through aromatic ring stacking.

General mechanism: Flavonoid polyphenol. PI3K inhibitor, sirtuin activator, NF-κB/NLRP3 suppressor. Senolytic (with dasatinib) through BCL-2/BCL-XL disruption.

Current Evidence

Dasatinib + quercetin senolytic combination tested in Phase I/II for Alzheimer's (SToMP-AD trial). Early results suggest brain senescent cell clearance. Quercetin alone shows anti-amyloid effects in preclinical models. Bioavailability enhanced by lipid formulations.

Clinical Status: Phase I/II (SToMP-AD senolytic trial). Available as supplement. Senolytic approach in early clinical investigation.

Safety Profile

Very safe as supplement. Dasatinib combination has higher side effect potential (fluid retention, cytopenias). Well-tolerated at standard supplement doses.

Key Research Questions

Frequently Asked Questions

Is quercetin a senolytic?

Yes. Quercetin combined with dasatinib is the most-studied senolytic combination. The landmark 2018 study (Xu et al., Nature Medicine) showed this combination selectively eliminates senescent cells and extends healthspan in mice. Human pilot trials show reduced senescent cell burden.

Quercetin dosage as senolytic

Senolytic protocols typically use quercetin 1000mg + dasatinib 100mg for 3 consecutive days per month (intermittent dosing). Continuous daily quercetin (500-1000mg) may provide antioxidant benefits but does not achieve senolytic concentrations.

View glossary entry →

← Back to Alzheimer's Disease Research